Journal
NANOMEDICINE
Volume 9, Issue 8, Pages 1193-1207Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.13.83
Keywords
cytotoxicity; gene therapy; in vivo test; polyethylene oxide; polymersomes; protamine
Funding
- National Science Foundation of China [81373366, 81373352]
- Shanghai JiaoTong University [YG2013MS52, YG2013MS62]
Ask authors/readers for more resources
Aim: The nonviral carrier system based on the triblock copolymer PEG-PCL-DEX (PPD) and protamine was developed for nucleic acid delivery. Materials & methods: Self-assembly occurred in the PEG continuous phase to form 'dextran-interior' polymersomes. siRNA can be condensed by protamine and encapsulated into PPD polymersomes in order to form the PPD-protamine siRNA nanoparticles by thermodynamically preferential partition between the PEG continuous phase and the dextran cavity. Results: This system can package siRNA into PPD polymersomes to form 145.2 +/- 8.02-nm (+/- standard deviation) nanoparticles, and the zeta-potential can be reduced to approximately 0 mV. PPD-protamine siRNA nanoparticles achieved cellular uptake of siRNA in SMMC-7721 cells with negligible cytotoxicity, and the GL3 gene expression can be reduced to 61.73 +/- 6.25%. A biodistribution study of nanoparticles suggested that the PPD-protamine siRNA nanoparticles mainly accumulated in liver. Conclusion: All of these results suggest that PPD-protamine carriers may offer a promising gene delivery strategy for the treatment of liver-related disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available